DL-threo-␤-Benzyloxyaspartate (DL-TBOA), a novel derivative of DL-threo-␤-hydroxyaspartate, was synthesized and examined as an inhibitor of sodium-dependent glutamate/aspartate (excitatory amino acid) transporters. DL-TBOA inhibited the uptake of [ 14 C]glutamate in COS-1 cells expressing the human excitatory amino acid transporter-1 (EAAT1) (K i ϭ 42 M) with almost the same potency as DL-threo-␤-hydroxyaspartate (K i ϭ 58 M). With regard to the human excitatory amino acid transporter-2 (EAAT2), the inhibitory effect of DL-TBOA (K i ϭ 5.7 M) was much more potent than that of dihydrokainate (K i ϭ 79 M), which is well known as a selective blocker of this subtype. Electrophysiologically, DL-TBOA induced no detectable inward currents in Xenopus laevis oocytes expressing human EAAT1 or EAAT2. However, it significantly reduced the glutamate-induced currents, indicating the prevention of transport. The dose-response curve of glutamate was shifted by adding DL-TBOA without a significant change in the maximum current. The K b values for human EAAT1 and EAAT2 expressed in X. laevis oocytes were 9.0 M and 116 nM, respectively. These results demonstrated that DL-TBOA is, so far, the most potent competitive blocker of glutamate transporters. DL-TBOA did not show any significant effects on either the ionotropic or metabotropic glutamate receptors. Moreover, DL-TBOA is chemically much more stable than its benzoyl analog, a previously reported blocker of excitatory amino acid transporters; therefore, DL-TBOA should be a useful tool for investigating the physiological roles of transporters.
Glutamate acts as an excitatory neurotransmitter in the mammalian central nervous system as well as a potent neurotoxin. The termination of neurotransmission is mediated by sodium-dependent high affinity glutamate/aspartate transporters. Glutamate transporters also play an important role in maintaining the extracellular glutamate concentration below neurotoxic levels and therefore contribute to the prevention of neuronal damage from excessive activation of glutamate receptors (Nicholls and Attwell, 1990; Rothstein et al., 1996; Gegelashvili and Schousboe, 1997; Kanai, 1997; Tanaka et al., 1997) . Some serious neuronal diseases, such as epilepsy, amyotrophic lateral sclerosis, Alzheimer's diseases, and cellular damage from a stroke, may be linked to the failure of transporters. Five subtypes of EAATs (EAAT1-5) have been cloned from mammalian tissues (Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Tanaka, 1993; Shashidharan et al., 1993 Shashidharan et al., , 1994 Arriza et al., 1994 Arriza et al., , 1997 Kawakami et al., 1994; Manfras et al., 1994; Fairman et al., 1995; Inoue et al., 1995) . These transporters couple the electrochemical gradient of three cotransported sodium ions and one countertransported potassium ion to that of glutamate (Zerangue and Kavanaugh, 1996) . A proton also is cotransported. In addition, a substrate-dependent chloride conductance provides a potential mechanism for dampening cell excitability (Fairman et al., 1995) . The transporter subtypes notably differ in the magnitude of this chloride flux relative to the flux of glutamate (Fairman et al., 1995; Wadiche et al., 1995; Arriza et al., 1997) .
Inhibitors of glutamate transporters are essential for elucidation of the intrinsic properties and physiological roles of transporters. A number of pharmacological agents have been shown to inhibit glutamate transport (Ferkany and Coyle, 1986; Bridges et al., 1991 Bridges et al., , 1993 Bridges et al., , 1994 Nakamura et al., 1993; Robinson et al., 1993; Arriza et al., 1994; Yamashita et al., 1995; Vandenberg et al., 1997) . Most of them indeed act as competitive substrates, inducing a transport current and a substrate-dependent chloride flux. Blocker-type inhibitors, which are not transportable, inhibit the transport of glutamate while letting transporters to be electrically silent. Moreover, they also suppress voltage-dependent pre-steady state charge movements, allowing kinetic information on the transporters to be obtained (Wadiche et al., 1995) . KA and DHKA block EAAT2 in the low-micromolar range, whereas Ϸ10 mM is required to block transport by EAAT1, EAAT3, and EAAT4 (Arriza et al., 1994; Fairman et al., 1995) . Recently, 2S4R4MG was shown to be a very potent blocker for EAAT2 and a substrate for EAAT1 (Vandenberg et al., 1997) . However, these compounds also activate ionotropic glutamate receptors (Gu et al., 1995) . As such, they can be valuable pharmacological tools for the study of EAAT2 in heterologous expression systems but cannot be used to determine the physiological role of this transporter in complex preparations. THA and t-2,4-PDC were found to be blockers for EAAT5 (Arriza et al., 1997) and substrates for EAAT1-4 (Arriza et al., 1994; Fairman et al., 1995) . THA also was demonstrated to be a ligand for N-methyl-D-aspartate receptors (Jane et al., 1994) ; therefore, pharmacological agents that are able to block EAATs without being transported and without affecting glutamate receptors are needed.
Our approach to the development of blockers of EAATs was the synthesis of derivatives of THA. We recently demonstrated that DL-TBzOAsp is a competitive blocker for bovine EAAT1 (glutamate/aspartate transporter type) (Lebrun et al., 1997) . However, because DL-TBzOAsp has an ester bond, it is unstable in aqueous solution (ester cleavage or acyl migration); therefore, we synthesized a more stable ethertype derivative, DL-TBOA. DL-TBOA showed potent inhibitory activity on the [ 14 C]glutamate uptake in COS-1 cells expressing human EAAT1 or EAAT2. Moreover, it proved to be highly selective for EAATs versus the glutamate receptors. Electrophysiological analysis demonstrated that DL-TBOA is a competitive blocker for human EAAT1 and EAAT2; it is indeed the most potent blocker for both EAAT1 and EAAT2 described to date.
Experimental Procedures
Materials. L-Glutamate was obtained from Nacalai Tesque (Kyoto, Japan). THA was from Sigma Chemical (St. Louis, MO). (Botson, MA) . L-CCG-III and L-CCG-IV were synthesized as described previously (Shimamoto et al., 1991) . DL-TBOA was synthesized in the same manner as DL-TBzOAsp, except for the use of benzyl bromide instead of acyl chloride (Lebrun et al., 1997) . The structure and purity (Ͼ95%) of the compound were confirmed with 400-MHz NMR. Stock solutions (100 mM) of the inhibitors, except for DL-TBzOAsp, were made in 0.1 M NaOH and stored at Ϫ20°. Stock solutions for DL-TBzOAsp were made in 50% dimethylsulfoxide without NaOH. DL-TBOA was stable for Ն1 week at room temperature; no noticeable decomposition was observed by NMR.
cDNA cloning. The cDNA clones coding for the human EAAT1 or EAAT2 were obtained by PCR performed on human brain cDNA (Clontech, Palo Alto, CA) using Ex Taq polymerase (Takara Shuzo, Shiga, Japan). To amplify the full-length EAAT-coding regions, sets of primers were designed according to the published nucleotide sequences (Shashidharan et al., 1993 (Shashidharan et al., , 1994 Arriza et al., 1994; Kawakami et al., 1994; Manfras et al., 1994) (set for EAAT1, 5Ј-AGCTGGAGCTCCACCCCTTACAAAATCAGAAAAGTTGTGTT-TTC-3Ј and 5Ј-AATTGGGTACCTGGTGCTCAAGAAAGTGTTTCT-TTATGTTAGTC-3Ј; set for EAAT2, 5Ј-AGCTGGAGCTCACCCCG-GCGTCCGCTTTCTCCCTCGCCCACATC-3Ј and 5Ј-AATTGGGTA-CCATAGGATACGCTGGGGAGTTTATTCAAGAATTTG-3Ј). Thirty cycles of amplification were carried out using a thermal cycle program (EAAT1, 1 min at 94°, 1 min at 55°, and 1 min at 72°; EAAT2, 1 min at 94°, 1 min at 45°, and 1 min at 72°). The PCR products (1.8 kbp for EAAT1 and 1.9 kbp for EAAT2) were cloned into pCR II according to the manufacturer's instruction for the Original TA Cloning Kit (InVitrogen, San Diego, CA). The obtained clones were subsequently analyzed by DNA sequencing. The clones containing EAATs were subcloned into pBluescript II SK Ϫ after digestion with SacI and KpnI for expression in Xenopus laevis oocytes. The plasmids were linearized with BssHII, and cRNA was transcribed from each of the cDNA constructs with T3 RNA polymerase and capped using the MEGAscript kits and Cap Analog (Ambion, Austin, TX). The eukaryotic expression vector pKDEMSS (Kitano et al., 1995) derived from pdKCR-dhfr was kindly donated by Dr. K. Kitano (Suntory Institute for Biomedical Research, Mishima-gun, Osaka, Japan). EAAT1 cloned in pCR II was digested with SpeI and XhoI and subcloned into the SpeI/SalI sites of pKDEMSS. EAAT2 cloned in pCR II was subcloned into pKDEMSS after digestion with EcoRI.
Transfection. COS-1 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37°under an atmosphere of 5% CO 2 . Cells were transfected by electroporation (1 ϫ 10 7 cells, 200 V, 975 F) with 10 g of the eukaryotic expression vector pKDEMSS containing each type of transporter cDNA. COS-1 cells transfected by the vector alone were used to control the level of the endogenous uptake of [ 14 C]glutamate. Transfected cells were seeded onto 96-well plates and cultured for 2 days before the uptake assay.
Measurements of [
14 C]glutamate uptake in transfected COS-1 cells. The subconfluent cells were washed two times with 300 l of modified phosphate-buffered saline that contained 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , 1 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM D-glucose, pH 7.4 (Yamashita et al., 1995) and preincubated in 300 l of the same buffer at 37°for 12 min. After aspiration of the buffer, cells were incubated with 1 M L-[
14 C]glutamate in 100 l of modified phosphate-buffered saline in the absence or presence of test compounds at various concentrations at 37°f or 12 min. To terminate the uptake, cells were washed three times with ice-cold buffer and solubilized with 100 l of 1 M NaOH. Radioactivity was measured by scintillation counting in 3 ml of ULTIMA-GOLD (Packard, Meriden, CT). Nonspecific incorporation was determined in sodium-free solution (140 mM choline chloride, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 20 mM HEPES, and 10 mM D-glucose, pH 7.4) (Nakamura et al., 1993) . Specific uptake of [ 14 C]glutamate is given relative to the control. The inhibition constants (K i values) were determined by Dixon and/or Lineweaver-Burk plots obtained for increasing concentrations of [
14 C]glutamate of 0.5-5 M. All values displayed are mean Ϯ standard error of at least three determinations.
Expression of EAAT in oocytes. Fifty nanograms of RNA coding for EAAT1 or EAAT2 was injected into stage V-VI defolliculated oocytes.
Electrophysiology. Two-electrode voltage-clamp recordings were made 2-4 days after injection with the use of the same apparatus and methods as described previously (Lebrun et al., 1997) .
Receptor binding assay. Rat brain synaptic membranes were prepared (Enna and Snyder, 1977) and modified (Murphy et al., 1988) as described previously and stored at Ϫ80°until use. On the day of the assay, the membrane suspension was incubated in a buffer containing 0.04% Triton X-100 at 37°for 30 min (Murphy et al., 1987 (Murphy et al., , 1988 . Triton X-100 was removed by centrifugation, and the pellet was washed twice with an assay buffer. Binding assays were performed according to published methods (London and Coyle, 1979; Murphy et al., 1987 Murphy et al., , 1988 Kawai et al., 1992) . Incubation conditions are described in the legend for Table 3 . mGluR assay. CHO cells stably expressing mGluR1, mGluR2, or mGluR4 were kindly donated by Prof. S. Nakanishi (Kyoto University, Kyoto, Japan). Agonist and antagonist activities on mGluR1 were determined by intracellular Ca 2ϩ concentration measurements on Fura-2/acetoxymethyl ester-loaded cells in the absence or presence of glutamate (10 M), respectively, as described previously (Kawabata et al., 1996) . Agonist activities on mGluR2 or mGluR4 were evaluated by measuring the inhibition of forskolin-induced cAMP formation as described previously (Hayashi et al., 1992 ). Antagonist activities were evaluated by measuring the rescue from the glutamate (10 M)-induced inhibition of forskolin-induced cAMP formation.
Results
We recently obtained the first competitive blockers for bovine EAAT1 (glutamate/aspartate transporter) by introducing some bulky acyl substituents on the ␤-hydroxyl group of DL-THA (Lebrun et al., 1997) . However, these derivatives are unstable in aqueous solution, particularly at basic pH, due to the presence of an easily cleavable ester bond and a possible intramolecular acyl migration from oxygen to nitrogen. Furthermore, they might be susceptible to esterases in biological preparations. To obtain a more stable derivative, we synthesized the ether-type analog DL-TBOA (Fig. 1) . This new compound proved to be stable even in a basic solution (disodium salt, pH 11.5) at room temperature. Because DL-TBOA was insensitive to the pH of a solution, it could be treated as a water-soluble sodium salt.
Cloning of human EAAT1 and EAAT2. To compare the inhibitory action of DL-TBOA with those of DL-TBzOAsp, our most potent blocker for EAAT1, and other known inhibitors on human EAAT1 and EAAT2, we first cloned these transporters by PCR from a human brain cDNA library. The sequence of our EAAT1 cDNA clone was identical to those of GenBank nos. D26443 (Kawakami et al., 1994) , L19158 (Shashidharan and Plaitakis, 1993) , and U03504 (Arriza et al., 1994) . On the contrary, there were some nucleotide differences between our EAAT2 cDNA clone and those of GenBank nos. U03505 (Arriza et al., 1994) , U01824 (Shashidharan et al., 1994) , and Z32517 (Manfras et al., 1994) . The nucleotide sequence of our clone has been submitted to the GenBank/EMBL/DDBJ Data Bank with accession no. D85884. The predicted human EAAT2 gene product reported here has 99% sequence identity with that of U03505, 98%
with that of U01824, and 92% with that of Z32517. Three amino acids (His19, Val211, and Phe347) in the amino acid sequence predicted from our clone were replaced in a very similar sequence predicted from UO3505, whereas these amino acids were conserved in the sequences predicted by the other clones; therefore, the differences do not seem to be errors introduced by the Taq polymerase. Because the characteristics of EAAT2 described below were very similar to those reported previously, we postulate that the substitutions have little effect on the transporter activity.
Inhibition of radiolabeled glutamate uptake in transfected COS-1 cells. Transfections were performed according to the electroporation method as described in Experimental Procedures. Transfected cells accumulated 5-10-fold more [
14 C]glutamate than vector-transfected cells. Uptake was reduced by Ͼ90% in Na ϩ -free solution. Michaelis constant (K m ) values for L-glutamate were 57 Ϯ 6.0 M for EAAT1 and 49 Ϯ 10 M for EAAT2.
Both DL-TBOA and DL-TBzOAsp markedly inhibited [ 14 C]glutamate (1 M) uptake in transfected cells in a dosedependent manner (Fig. 2) . On EAAT1, DL-TBOA was more potent than DL-TBzOAsp, with almost the same level of ac- (Kawai et al., 1992; Nakamura et al., 1993; Yamashita et al., 1995) . L-CCG-IV, a stereoisomer of L-CCG-III, was reported to be nearly as potent as L-CCG-III on human glutamate transporter-1 expressed in COS-7 cells (Yamashita et al., 1995) . It showed only a weak affinity (IC 50 ϭ 900 M) in this work, which is consistent with its poor inhibitory activity on the uptake by the glial plasmalemmal vesicle and synaptosomes (Kawai et al., 1992; Nakamura et al., 1993) . On EAAT2, the inhibitory effect of DL-TBOA was much stronger than that of DL-TBzOAsp and DL-THA (IC 50 ϭ 5.5, 126, and 31 M, respectively). The potency of DL-TBOA was comparable to that of L-CCG-III (IC 50 ϭ 4.6 M). DHKA, known to be a selective blocker of EAAT2, inhibited the uptake on EAAT2 with an IC 50 value of 196 M, whereas it had no effect on EAAT1 at a concentration as high as 1 mM. Recently, 2S4R4MG was reported to be the most potent blocker for EAAT2 and a substrate for EAAT1 in an electrophysiological study using X. laevis oocytes expressing EAAT1 or EAAT2 (Vandenberg et al., 1997) . In this study, 2S4R4MG (IC 50 ϭ 69 M) proved to be more potent than DHKA on EAAT2 but less potent than DL-TBOA.
The uptake inhibition mechanism of these compounds was examined by a kinetic analysis. Initial rates of glutamate uptake were measured for various concentrations of glutamate and the inhibitors (Fig. 3) . Dixon plots gave straight lines, which intersected at a common point, indicating a competitive inhibition. The inhibition constants (K i values) are summarized in Table 2 .
Electrophysiological studies on X. laevis oocytes. To determine whether DL-TBOA is a substrate or a blocker of EAAT1 and EAAT2, we performed an electrophysiological analysis of its effect on X. laevis oocytes injected with cRNA encoding EAAT1 or EAAT2. DL-TBOA (100 M) did not elicit a detectable current in voltage-clamped oocytes expressing EAAT1 or EAAT2. However, the inward current induced by glutamate (100 M) was significantly reduced in the presence of DL-TBOA (100 M) (Fig. 4) .
A Schild analysis of the effects of increasing concentrations of DL-TBOA on glutamate dose responses demonstrated that DL-TBOA is a competitive blocker of EAAT1 and EAAT2. For EAAT1, the apparent affinity for glutamate was shifted from 14 Ϯ 1 to 27 Ϯ 2 and 54 Ϯ 3 M in the presence of 10 and 30 M DL-TBOA, respectively, without a significant modification of the maximum current (Fig. 5A) . A similar parallel shift of the dose-response curve was obtained on EAAT2. The apparent affinity for glutamate was shifted from 31 Ϯ 3 to 152 Ϯ 4, 436 Ϯ 18, and 1410 Ϯ 74 M in the presence of 1, 3, and 10 M DL-TBOA, respectively (Fig. 5B) . The agonist dose ratio (dr) In both subtypes, straight-line plots are obtained, and they intersect at a common point (ϪK i ), indicating that DL-TBOA inhibited the glutamate uptake in a competitive manner. The Dixon plots shown are from a single representative experiment. The K i values of other inhibitors were obtained in the same manner and are summarized in Table 2 , where they are presented as the mean Ϯ standard error of three independent experiments.
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at ASPET Journals on May 9, 2017 molpharm.aspetjournals.org Downloaded from was calculated at each blocker concentration, and log(dr Ϫ 1) was plotted against log[DL-TBOA] (Fig. 5C ). Antagonism equilibrium dissociation constants (K b values) of 9.0 M for EAAT1 and 116 nM for EAAT2 were obtained from a linear fit of the data with slopes of 1.01 and 1.06, respectively. Activity on ionotropic glutamate receptors and mGluRs. A key requirement for blockers of EAATs to be valuable pharmacological tools is selectivity toward EAATs versus glutamate receptors. We analyzed the activity of our derivatives on the ionotropic glutamate receptors by binding assays and on the mGluRs by calcium influx measurements (mGluR1) or cAMP formation monitoring (mGluR2 and mGluR4). DL-TBOA showed only a weak affinity toward ionotropic glutamate receptors. In binding competition with (Table 3) . DL-TBOA did not show any agonist or antagonist activity on mGluRs (mGluR1, mGluR2, and mGluR4) at a concentration of 100 M (data not shown).
Discussion
The results of this study demonstrated that DL-TBOA is a potent competitive blocker of EAAT1 and EAAT2. Furthermore, it showed no activity on the metabotropic receptors tested so far (mGluR1, mGluR2, and mGluR4) at a concentration of 100 M and was only weakly active on the ionotropic receptors. Thus, this compound proved to be highly selective for EAATs versus the glutamate receptors. The previously described blockers of EAAT2 lacked such a selectivity. KA and 2S4R4MG are high affinity ligands for KA receptors, and DHKA is active on both KA receptors and EAAT2 within the same concentration range; therefore, DL-TBOA will be the blocker of choice for studying the physiological roles of EAATs.
We determined the kinetic parameters of DL-TBOA on EAAT1 and EAAT2 in two different assay systems: the uptake in COS-1 cells and the voltage-clamp study in X. laevis oocytes. It should be noted that the K i value for DL-TBOA obtained from the uptake assay was significantly higher than the K b value from the electrophysiological assay. The discrepancy was lower in the case of EAAT1 (K i ϭ 42 M, K b ϭ 9 M) than in the case of EAAT2 (K i ϭ 5.7 M, K b ϭ 0.12 M). The K b values for DHKA and 2S4R4MG on EAAT2 were determined previously (9 and 3.4 M, respectively) with a electrophysiological study using X. laevis oocytes (Arriza et al., 1994; Vandenberg et al., 1997) . Their affinity in COS-1 cells were also tested and proved to be underestimated. System differences might be attributed to differences in lipid composition, post-translational modification, and other factors (Arriza et al., 1994) . Of importance could be that COS-1 cells are not voltage-clamped as opposed to X. laevis oocytes. Presumably, transport over a 12-min interval would cause a significant depolarization and, as such, would slow the transport rate. The blocker could suppress such a depolarization and restore the transport rate. The control cells that take up glutamate would be more depolarized than the blocked ones; therefore, the relative measurement would lead to underestimation of the apparent activity of blockers. EAAT1 displays a stronger substrate-dependent chloride conductance than EAAT2 (Wadiche et al., 1995) . This chloride conductance may reduce the membrane depolarization and therefore limit the underestimation of the affinity for EAAT1. We nevertheless acknowledge that Arriza et al. (1994) observed a lower discrepancy in the affinity of DHKA on EAAT2 expressed in COS-7 cells (K i ϭ 23 M) versus in X. laevis oocytes (K b ϭ 9 M).
It would be plausible that a particular conformation of glutamate or aspartate can be recognized by the substratebinding sites of transporters. TBOA is a flexible molecule that can adopt several conformations. For the development of selective blockers, it is to elucidate the active conformation for binding to EAATs. In recent studies, assessment was attempted of the conformational requirements for glutamate binding to EAATs (Shimamoto et al., 1991; Bridges et al., 1991 Bridges et al., , 1993 Bridges et al., , 1994 Kawai et al., 1992; Nakamura et al., 1993; Yamashita et al., 1995; Vandenberg et al., 1997) . Bridges et al. (1991 Bridges et al. ( , 1993 Bridges et al. ( , 1994 proposed that a folded form of glutamate binds to EAATs while an extended form of aspartate is Inhibition constants (K i ) were obtained from initial rates of glutamate uptake measured at various concentrations of glutamate and inhibitors (Fig. 3) . Antagonist equilibrium dissociation constants (K b ) were obtained from Schild analysis (Fig. 5) . 
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adopted. This hypothesis seemed to be reasonable because the functional groups (two carboxylates and an amino group) of these conformers and those of the active compounds can be well superimposed (Bridges et al., 1991 (Bridges et al., , 1993 (Bridges et al., , 1994 . Thus, we assumed that the active conformation of TBOA would be an extended one. Besides the conformational requirements described above, the diastereomeric properties of the compounds are recognized by transporters. L-Glutamate is a high affinity substrate, whereas D-glutamate is poorly transported. On the other hand, both enantiomers of aspartate are known to be excellent substrates of EAATs. Moreover, four diastereomers of ␤-hydroxyaspartate (L-and D-, and threo-and erythro-) were nearly equal in activity (Robinson et al., 1993) . We suggest that such a permissiveness in structure could be lost in TBOA, in which the small hydroxyl group of THA has been replaced by a bulky benzyl group. We propose that the bulky substituent in TBOA plays a very important role in conferring blocking activity, whereas the hydroxyl of THA is simply tolerated in the pharmacophore (Lebrun et al., 1997) . Therefore, the orientation of this substituent relative to the aspartate framework should be very important. The synthesis of the pure stereoisomers of TBOA and erythro-isomers is under way. The elucidation of the binding conformation and blockade mechanism might make it possible to develop more potent, and perhaps more selective, EAAT blockers.
So far, DL-TBOA has proved to be the most potent blocker for EAAT1 and EAAT2, with high selectivity toward EAATs versus the glutamate receptors. Moreover, our preliminary results in this electrophysiological study indicated that DL-TBOA also was a blocker for the mouse EAAC1 (EAAT3 subtype). Therefore, this compound opens the way for the mechanistic and kinetic studies of EAAT1 and EAAT3. It should prove useful in determination of the physiological roles of EAATs in various preparations. 
